Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An exploratory clinical study of camrelizumab combined with radiotherapy in the treatment of postoperative or late recurrence of colorectal cancer

ABSTRACT: Interventions: Test group :Camrelizumab + radiotherapy Primary outcome(s): Progression-free survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2760326 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial

Project description:Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial

| PRJNA1114074 | ENA

An exploratory study on optimizing the administration time of furquintinib combined with camrelizumab in the third-line treatment of MSS late colorectal cancer

Project description:Interventions: Test group:Camrelizumab + Fruquintinib Primary outcome(s): progression-free survival Study Design: Single arm

| 2716835 | ecrin-mdr-crc

Combined anti-C1-INH and Radiotherapy against Glioblastoma

Project description:Animals with intracranial glioblastoma of the NS1 cells line were treated with anti-C1-INH +/- radiotherapy or were untreated control animals.

2022-10-19 | E-MTAB-12296 | biostudies-arrayexpress

A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer

Project description:Interventions: control group:Camrelizumab;experimental group 1:Camrelizumab;experimental group:bevacizumab / apatinib Primary outcome(s): complete pathological response rate Study Design: Non randomized control

| 2759992 | ecrin-mdr-crc

Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial

Project description:Lipid accumulation of skeletal muscle can be modulated after treatment of metronomic chemotherapy, while the detail molecular mechanisms are unclear. We used metronomic dose of 5-FU to treat C2C12 cell in vitro. RNA sequencing showed the expression of lipid metabolism related genes was changed after treatment.

2025-12-02 | GSE268030 | GEO

Longitudinal Plasma Nano-proteomics Analysis Reveals Acute Systemic Responses to Radiotherapy and Predictive Biomarkers of Late Toxicity

Project description:Radiotherapy induces systemic changes beyond the targeted tumour site, yet the biological mechanisms driving these effects remain poorly understood. Here, we apply the Nano-proteomics pipeline to longitudinally profile systemic responses to radiotherapy in patients with prostate, bladder, and head and neck cancers. Weekly plasma samples collected before and during treatment were analysed by mass spectrometry and revealed acute plasma proteomic changes. The most significant systemic effects occurred within the first two weeks of radiotherapy, highlighting a critical window for biomarker discovery. Across all cohorts, common biological processes were enriched, characterized by early activation of inflammatory and immune pathways, followed by later structural reorganization and immune resolution, regardless of irradiated tissue or concurrent treatments. Despite this shared acute response, distinct protein mediators were dysregulated in a tumour-specific manner. Notably, in prostate cancer patients, baseline proteomics revealed 28 biomarkers associated with late bowel and urinary toxicities, supporting the potential of plasma proteomic biomarkers to identify patients at increased risk of radiotherapy-induced toxicity. This study underscores the value of longitudinal proteomics in uncovering systemic effects of radiotherapy and paves the way for developing predictive biomarkers to guide personalized radiotherapy strategies aimed at minimizing adverse effects.

2026-06-08 | PXD071492 | Pride

Clinical Trial of Camrelizumab Combined with Cetuximab and Chemotherapy Drugs to treat Ras Wild Colorectal Cancer

Project description:Interventions: 1:Camrelizumab, Cetuximab, and chemotherapeutics.;2:Camrelizumab, Cetuximab and chemotherapeutics. Primary outcome(s): ORR Study Design: Non randomized control

| 2688526 | ecrin-mdr-crc